BRAF Gene Mutation Analysis
Also known as: Oncomine Dx Target Test
Use
BRAF is an important member of the mitogen-activated protein kinase (MAPK) pathway that influences cell proliferation. This test will detect all V600 mutations of the BRAF oncogene frequently found in human cancers, such as melanoma, colorectal cancer, lung cancer, ovarian cancer, thyroid cancer, and hairy cell leukemia, allowing the determination of drug response, aiding the diagnosis and providing prognosis information. More than 90% of mutations are the V600E (c1799T>A) mutation, but other V600 mutations have been reported.
Special Instructions
Ensure a pathology report accompanies the specimen. Testing delays will occur if the pathology report is missing. Contact customer service at 800-345-4363 for inquiries.
Limitations
This assay can detect 5% mutation amid a backdrop of wild-type DNA. The test is not FDA-cleared or approved, as both its development and performance characteristics were established by Labcorp.
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (FFPE)
Volume
FFPE tissue block or four unstained slides and one matching H&E-stained slide at 5 μM; 5 to 10 mL FNA in CytoLyt container
Minimum Volume
Two unstained slides and one matching H&E-stained slide at 5 μM; 5 mL FNA
Container
FFPE tissue block or slides
Storage Instructions
Maintain specimen at room temperature. If specimen is to be stored prior to shipment, store at 2°C to 8°C. Store FFPE block or slides, FNA in CytoLyt container at room temperature.
Causes for Rejection
Tumor block containing no tumor; broken or stained slides; specimen does not meet collection criteria.